2-{[(4-chlorophenyl)methyl]sulfanyl}-5-(furan-2-yl)-1,3,4-oxadiazole

Catalog No. :
ACRHGZ427
CAS No. :
119611-17-5
Molecular Formula :
C13H9ClN2O2S
Molecular Weight :
292.75

IUPAC Name:2-((4-chlorobenzyl)thio)-5-(furan-2-yl)-1,3,4-oxadiazole

2-{[(4-chlorophenyl)methyl]sulfanyl}-5-(furan-2-yl)-1,3,4-oxadiazole structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g90%$323.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name2-{[(4-chlorophenyl)methyl]sulfanyl}-5-(furan-2-yl)-1,3,4-oxadiazole
IUPAC Name2-((4-chlorobenzyl)thio)-5-(furan-2-yl)-1,3,4-oxadiazole
MDL No.MFCD02082468
Molecular FormulaC13H9ClN2O2S
Molecular Weight292.75
SMILESClC1=CC=C(CSC2=NN=C(C3=CC=CO3)O2)C=C1
InChI KeyWWHYWNDHBOVYEF-UHFFFAOYSA-N
Synonym4-CHLOROBENZYL 5-(2-FURYL)-1,3,4-OXADIAZOL-2-YL SULFIDE;2-[(4-CHLOROBENZYL)SULFANYL]-5-(2-FURYL)-1,3,4-OXADIAZOLE;2-{[(4-chlorophenyl)methyl]sulfanyl}-5-(furan-2-yl)-1,3,4-oxadiazole;1,3,4-Oxadiazole, 2-[[(4-chlorophenyl)methyl]thio]-5-(2-furanyl)-
CAS No.119611-17-5

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P330-P362-P403+P233-P501

Synthetic Route by SureRoute

1. ACRHGZ427 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACRHGZ427 route product structure diagram
    ACRHGZ427119611-17-5
Inquiry

2. ACRHGZ427 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACRHGZ427 route product structure diagram
    ACRHGZ427119611-17-5
Inquiry

Comments (0)